Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmaceutics
Autors principals: Bonizzi, Arianna, Truffi, Marta, Sevieri, Marta, Allevi, Raffaele, Sitia, Leopoldo, Ottria, Roberta, Sorrentino, Luca, Sottani, Cristina, Negri, Sara, Grignani, Elena, Mazzucchelli, Serena, Corsi, Fabio
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6723888/
https://ncbi.nlm.nih.gov/pubmed/31382388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11080384
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars